Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Correction to: Leukemia (2012) 26, 149–157; doi:10.1038/leu.2011.196 Since the publication of this paper, the authors have noticed that one of the author names in the appendix was incorrectly listed as Hareth Nari. It should be listed as follows: Hareth Nahi, Karolinska University Hospital, Stockhol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2012-05, Vol.26 (5), p.1153-1153
Hauptverfasser:	Kumar, S K, Lee, J H, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, LeLeu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladeé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, S V
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/67/1059/99 692/699/67/1990/804 692/700/1750/1976 Cancer Research corrigendum Critical Care Medicine Erratum Hematology Intensive Internal Medicine Medicine Medicine & Public Health Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Correction to: Leukemia (2012) 26, 149–157; doi:10.1038/leu.2011.196 Since the publication of this paper, the authors have noticed that one of the author names in the appendix was incorrectly listed as Hareth Nari. It should be listed as follows: Hareth Nahi, Karolinska University Hospital, Stockholm, Sweden.
ISSN:	0887-6924 1476-5551
DOI:	10.1038/leu.2012.15